Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) saw a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 9,006 shares, a growth of 149.8% from the February 26th total of 3,605 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 16,592 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On Daxor

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. bought a new stake in shares of Daxor Corporation (NASDAQ:DXR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned 0.18% of Daxor as of its most recent SEC filing. 1.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on DXR shares. Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Monday, December 29th. Lake Street Capital initiated coverage on shares of Daxor in a research note on Wednesday, February 11th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Daxor Stock Performance

Shares of DXR stock traded down $0.07 during mid-day trading on Thursday, reaching $10.33. 1,758 shares of the stock traded hands, compared to its average volume of 9,022. The stock’s fifty day simple moving average is $12.08 and its two-hundred day simple moving average is $12.66. Daxor has a 1-year low of $7.10 and a 1-year high of $14.76.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.